HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced the establishment of a global research and development center within the Hong Kong Science Park. This strategic move positions HutchMed amidst a thriving ecosystem of over 270 biotechnology companies, fostering collaboration and innovation.
Specializing in translational medicine, HutchMed leverages artificial intelligence to advance drug discovery and development. The new R&D center will serve as a hub for the company’s efforts to transform scientific insights into clinical applications, potentially accelerating the pipeline of new therapies and enhancing patient outcomes.- Flcube.com
